Facebook
Twitter
LinkedIn
ForwardEmbracing Multi-Disciplinary Care for Advanced Prostate Cancer: A Case-Based Update Webcast (2025)
This is an ongoing course on advanced prostate cancer at the annual AUA since 2012 and the changes over the last decade continue to be breathtaking! In the early years, it was all about metastatic castrate-resistant prostate cancer (mCRPC) with multiple new therapeutic advances starting in 2010 followed by novel oral antiandrogens and a focus on bone-targeted agents. Later, it expanded to cover hormone sensitive (HS) advanced disease due to the new data on chemotherapy and androgen synthesis inhibitors extending survival in new M1 patients. A few years later, the topic of non-metastatic CRPC (M0 CRPC) was added due to emerging data on use of second and third generation oral antiandrogens in these men. In more recent years, the course expanded information on HS new M1 disease with emerging data that five distinct new therapeutics all improve survival for men with new metastatic prostate cancer. Some may have argued that the value of the course for urologists was a stretch back in 2012 because of the belief by some physicians that mCRPC should be managed only by medical oncologists. However, now the course is very relevant to practicing urologists as most M0 CRPC and virtually all new M1 HS patients are initially managed by urologists and their APP practice colleagues.
Using a case-based and multidisciplinary format, we will continue to push the boundaries of knowledge to urologists and their teams in covering this new toolbox of novel therapies. In addition, we will cover the latest advance in the latest targeted therapies and "Triple" therapy for HS M1 disease. The course faculty will be an academic urologist, a LUGPA Private Practice Urologist, and an Academic Medical Oncologist.
ACKNOWLEDGEMENTS:
This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral antiandrogens. Furthermore, to recognize high-volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team.
- Non-Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): The learner will be skilled to diagnose M0 CRPC and be able to educate patients about using either enzalutamide or apalutamide or darolutamide added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three oral agents and to educate patients about side-effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease Non-metastatic Castrate-Resistant Prostate Cancer (M0 CRPC): Diagnose M0 CRPC and be able to educate patients about using novel oral antiandrogens added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these novel oral agents and to educate patients about side effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease state.
- Metastatic Castrate-Resistant Prostate Cancer (M1 CRPC): Describe and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and be able to educate their patients on treatment options and participate in a multidisciplinary team caring for men with this disease state of far-advanced prostate cancer.
- Describe that advanced prostate cancer is a complex group of disease states with an ever-changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients.
- Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents, and novel AR targeted agents emerging in 2025 and beyond.
FACULTY DISCLOSURES
| Name | Company Name | Relationship Type | End Date |
| Morgans, Alicia | No relevant financial relationships to disclose | ||
| Morris, David Scott | No relevant financial relationships to disclose | ||
| Moul, Judd W. | No relevant financial relationships to disclose | ||
EDUCATION COUNCIL DISCLOSURE
Education Council Disclosures_June 2024.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Workgroup Disclosures_June 2024.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
ACCREDITATION INFORMATION
Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Release Date: May, 2025
Expiration Date: May, 2026
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation